Beam Therapeutics announces groundbreaking results from its Phase 1/2 trial of BEAM-302, demonstrating the first-ever clinical genetic correction for Alpha-1 Antitrypsin Deficiency (AATD), offering hope for a potential one-time cure for this genetic disorder...
TIGR (Tandem Interspaced Guide RNA) systems use RNA guides to target specific DNA sites, offering a compact and modular alternative to CRISPR. Scientists at MIT and the Broad Institute discovered over 20,000 TIGR-associated proteins, some capable of precise DNA cutting, potentially expanding genome...
Avance Biosciences™ announces CLIA registration, expanding its high-complexity laboratory testing capabilities for clinical trials, regulatory submissions, and companion diagnostics. This milestone strengthens its commitment to high-quality, regulatory-compliant testing solutions that accelerate drug...
A groundbreaking gene therapy using rAAV8.hRKp.AIPL1 has restored vision in 11 children with AIPL1-related retinal dystrophy (LCA4), who were blind at birth. Published in The Lancet, the study shows significant improvements in visual acuity and retinal preservation, supporting expedited approval...
Well, well, well... it was a TREAT — and a big one for a lucky few! Avance fully embraced Halloween last Thursday with a costume contest, candy galore, and a pizza party. The costume contest was a great way to bring everyone together, with employees voting for winners in five fun categories [...]
Avance Biosciences is excited to announce its participation in the upcoming SITC Conference, taking place from November 6-10, 2024, in Houston TX. This premier event is focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. [...]
Avance Biosciences™ offers top-tier GLP & GMP compliant services in assay development, validation, & sample testing for biopharma. Visit our booth to explore how we support drug discovery, development, & manufacturing with precision & expertise. [...]
Avance Biosciences is excited to announce its participation in the upcoming Immunogenicity & Bioassay Summit, taking place from October 15-18, 2024, in Washington, DC. As the premier immunogenicity and bioassay event in the U.S., this summit provides an excellent platform for us to connect with industry [...]
Avance Biosciences is excited to announce its participation in the upcoming 2nd CRISPR-Based Therapy Analytical Development Summit, taking place from September 17-19, 2024, in Boston, MA. This premier event is a key gathering for professionals and innovators in the gene editing and CRISPR fields.[...]
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel. Exa-cel is the world’s first CRISPR-based gene therapy and the first gene therapy available in Europe for treating severe beta-thalassaemia...
